Last reviewed · How we verify

equimolar oxygen-nitrous oxide mixture

Centre Hospitalier Universitaire de Nīmes · FDA-approved active Small molecule

An equimolar mixture of oxygen and nitrous oxide provides analgesia and anxiolysis through nitrous oxide's effects on central nervous system receptors while maintaining adequate oxygenation.

An equimolar mixture of oxygen and nitrous oxide provides analgesia and anxiolysis through nitrous oxide's effects on central nervous system receptors while maintaining adequate oxygenation. Used for Acute pain relief in emergency settings, Anxiolysis and analgesia during minor procedures, Procedural sedation.

At a glance

Generic nameequimolar oxygen-nitrous oxide mixture
SponsorCentre Hospitalier Universitaire de Nīmes
Drug classInhalational anesthetic/analgesic mixture
TargetNMDA receptor antagonist (nitrous oxide component)
ModalitySmall molecule
Therapeutic areaAnesthesia, Acute Pain Management
PhaseFDA-approved

Mechanism of action

Nitrous oxide acts as a dissociative anesthetic and analgesic by modulating NMDA receptors and other central pathways, while the equimolar oxygen component (50% each) ensures adequate oxygenation and reduces the risk of hypoxia. This combination is commonly used for acute pain relief and anxiolysis in emergency and procedural settings, allowing rapid onset and offset due to nitrous oxide's rapid kinetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: